On January 27, Sherry Paul, Morgan Stanley senior portfolio manager, joined CNBC’s ‘Closing Bell’ to discuss the state of equity markets and whether more volatility is ahead. Pre-Davos market was characterized by overwhelming bullish sentiment, and the post-Davos environment is marked by renewed volatility, the Sell-America trade, a rallying gold price, and a consistently weak dollar. Paul noted a critical shift in global discourse coming out of Davos: the transition from the term de-globalization to the new world order. She explained that while de-globalization implied a more passive conscious uncoupling, the phrase new world order carries a harsher tone of urgency. This shift necessitates an immediate re-imagining of supply chains, partnerships, and the advancement of domestic AI and automated manufacturing in the US, especially given the lower dollar.
Paul asserts that while more volatility is undoubtedly ahead as these changes unfold, it should be viewed as a sign of an emergent rather than a negative market. She described this emergence as a move away from the MAG7 toward ‘magnificent thematics.’ These themes include the new world order, AI automation, innovation, and longevity. By following these thematics, investors can identify specific sector weightings to overweight rather than simply moving their holdings to cash. Regarding her 2026 investment thesis, Paul recommends leaning into the other 473 companies of the S&P 500 rather than concentrating on the mega-caps. Her central argument is that every company is now effectively a tech company. The race for productivity, cost-cutting, and advancement is moving so rapidly that modeling these technological applications is essential for survival.
That being said, we’re here with a list of the 15 stocks that should double by 2030.
Our Methodology
We sifted through several financial media reports and stock screeners to compile a list of the top stocks that will double in 2030. We then picked 15 stocks that analysts and hedge funds are still bullish on. The stocks are ranked in ascending order of the number of hedge funds that have stakes in them, as of Q3 2025.
Note: All data was sourced on February 4.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
15 Stocks That Should Double by 2030
15. CRISPR Therapeutics (NASDAQ:CRSP)
Number of Hedge Fund Holders: 21
CRISPR Therapeutics (NASDAQ:CRSP) is one of the stocks that should double by 2030. On January 30, Citizens maintained an Outperform rating on CRISPR Therapeutics while reducing the price target from $86 to $80. The firm highlighted that much of the pipeline remains undervalued and noted that the company could begin late-stage development for up to seven opportunities in 2027.
Earlier on January 6, Bank of America analyst Alec Stranahan reduced the firm’s price target for CRISPR Therapeutics (NASDAQ:CRSP) to $90 from $93 while maintaining a Buy rating. This sentiment was posted as the firm adjusted price targets across its US Biopharmaceuticals coverage.
BofA specifically noted that recently, various factors have aligned, such as rewards for positive data, large-cap biopharma investing in M&A & licensing, an increasing private company backlog, better capital access, and minimal drug price regulation effects. The firm suggested that biotech has returned, though the primary uncertainty remains the trend’s longevity.
CRISPR Therapeutics (NASDAQ:CRSP) is a gene editing company that develops gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.
14. Summit Therapeutics Inc. (NASDAQ:SMMT)
Number of Hedge Fund Holders: 27
Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the stocks that should double by 2030. On January 29, Summit Therapeutics announced that the US FDA accepted its BLA (Biologics License Application) for ivonescimab used in combination with chemotherapy. The treatment targets patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC (non-small cell lung cancer) who have progressed after TKI therapy. The FDA established a PDUFA goal action date of November 14 this year, for its regulatory decision.
The submission is supported by data from the Phase III HARMONi global study, which compared the ivonescimab combination against a placebo and chemotherapy regimen. Ivonescimab is a bispecific antibody designed to simultaneously block PD-1 and VEGF, potentially offering higher efficacy by targeting the tumor microenvironment more precisely than previous therapies.
This specific patient population represents a significant unmet need, with 14,000+ individuals in the US eligible for treatment annually. While currently approved in China, ivonescimab remains an investigational therapy in Summit’s licensed territories, including North America and Europe.
Summit Therapeutics Inc. (NASDAQ:SMMT) is a biopharmaceutical company that discovers, develops, and commercializes patient, physician, caregiver, and society-friendly medicinal therapies.
Hedge Fund Resource Center